EC Number   |
Application |
Reference |
|---|
   3.4.24.79 | diagnostics |
increased pregnancy-associated plasma protein-A is a marker for peripheral atherosclerosis, Linz Peripheral Arterial Disease Study |
683365 |
| 3.4.24.79 | diagnostics |
PAPP-A is a circulating biomarker for acute coronary syndrome |
683504 |
| 3.4.24.79 | diagnostics |
the enzyme is a highly specific marker for coronary heart disease |
683359 |
| 3.4.24.79 | medicine |
a detailed analysis is performed of first trimester screening results in singleton pregnancies conceived using assisted reproductive technologies and non-assisted reproductive technologies pregnancies. A record linkage study compared outcomes in 1739 assisted reproductive technologies-conceived and 50.253 naturally conceived pregnancies. Assisted reproductive technologies pregnancies have reduced first trimester screening PAPP-A levels leading to an increased likelihood of receiving a false-positive result and having a CVS/amniocentesis. Lower PAPP-A may reflect impairment of early implantation with some forms of assisted reproductive technologies |
698200 |
| 3.4.24.79 | medicine |
a prospective screening study for trisomy 21 in singleton pregnancies is carried out by a combination of maternal age, fetal nuchal translucency, free beta-hCG and PAPP-A in a one-stop-clinic for first-trimester assessment of risk at 11-13 weeks of gestation. All three trisomies (13,18 and 21) are associated with increased maternal age, increased fetal nuchal translucency and decreased maternal serum PAPP-A |
698199 |
| 3.4.24.79 | medicine |
administation of insulin-like growth factor binding protein (IGFBP)-4 causes significant increase in bone formation parameters, possibly through increased IGF bioavailability via proteolysis of insulin-like growth factor binding protein (IGFBP)-4 |
638946 |
| 3.4.24.79 | medicine |
contribution of maternal variables that influence the measured concentration of free beta-human chorionic gonadotropin and PAPP-A, and the interaction between these covariates, in first-trimester biochemical screening for trisomy 21 are analysed. In a multicenter study of prospective first-trimester biochemical screening for trisomy 21 it is shown that it is essential to adjust the measured values of free beta-human chorionic gonadotropin and PAPP-A for maternal and pregnancy characteristics |
701361 |
| 3.4.24.79 | medicine |
enhancing IGF bioavailability by PAPP-A can be a powerful strategy in the treatment of certain metabolic diseases such as osteoporosis |
683411 |
| 3.4.24.79 | medicine |
it is examined whether maternal Rhesus status has any effect on the levels of first-trimester markers free beta-human chorionic gonadotropin, PAPP-A and nuchal translucency. First-trimester markers from pregnant women are converted into multiples of medians and corrected for maternal weight, ethnicity, and smoking status. Totally, 15045 normal, singleton pregnancies are retrieved with full records. Maternal Rhesus status does not influence the levels of free beta-human chorionic gonadotropin and PAPP-A in the first trimester of pregnancy in this almost exclusively Caucasian population studied. Therefore, correction for maternal Rhesus status is not suggested |
700920 |
| 3.4.24.79 | medicine |
levels of PAPP-A and C-reactive protein in pre-eclampsia and their association with the mean arterial blood pressure are determined. 67 women with pre-eclampsia symptoms are matched with 56 normal pregnant controls for gestational age, maternal age and parity. Both of the groups are third trimester. PAPP-A and C-reactive protein are measured in serum. Maternal serum levels of PAPP-A and C-reactive protein are increased in women with pre-eclampsia compared to controls |
699711 |
